Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi US

Latest From Sanofi US

Consistency, Not Fireworks: US FDA’s Novel Approvals Times Stick Close To PDUFA Schedule

CDER holds steady with a median time to approval of 11 months, while CBER posts 10.5 month median review time for its largest novel approvals class.

US FDA Performance Tracker Pink Sheet Perspectives

Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data

Some drugs recorded significant increases in Medicare gross spending between the periods covered by publicly available data and what CMS had access to internally, which contributed to their unexpected presence on the list.

Reimbursement Policy

Medtech’s Role In The Future Of GLP-1 Therapy

As well as making waves in the treatment of obesity, debate has been stirring around the ability of GLP-1s to combat drug addiction, manage heart disease and also protect individuals against Parkinson’s disease. How can medtechs get in on the potential gains? 

Behavioral Health Business Strategies

The Book Of GLP-1s: For Medtech They Giveth, As Well As Taketh Away

GLP-1 inhibitors for weight loss are rapidly threatening several medtech segments; however, in ensuring their long-term efficacy, digital health companies could benefit.

Digital Health Platform Technologies
See All

Company Information

  • Industry
  • Pharmaceuticals